Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats

被引:0
作者
Ming-peng Fu
Zi-long Guo
Hong-ling Tang
Hui-fen Zhu
Guan-xin Shen
Yong He
Ping Lei
机构
[1] Huazhong University of Science and Technology,Department of Immunology, School of Basic Medicine, Tongji Medical College
[2] Zhongnan Hospital of Wuhan University,Department of Nuclear Medicine and PET Center
来源
Current Medical Science | 2020年 / 40卷
关键词
bispecific antibody; single-chain tandem single-chain variable fragments; diabody; transferrin receptor; CD3;
D O I
暂无
中图分类号
学科分类号
摘要
Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we constructed TfR bispecific T-cell engager (BiTE) in two extensively applied formats, including single-chain tandem single-chain variable fragments (scFvs) and double-chain diabodies, and evaluated their functional characterizations in vitro. Results demonstrated that TfR-BiTE in both formats directed potent killing of TfR+ HepG2 cells. However, compared to two-chain diabodies, scFvs were more efficient in antigen binding and TfR+ target killing. Furthermore, different domain orders in scFvs would also be evaluated because single-TfR-CD3-His was preferable to single-CD3-TfR-His in immunotherapeutic strategies. Thus, the single-chain tandem TfR-CD3 format was favored for further investigation in cancer therapy.
引用
收藏
页码:28 / 34
页数:6
相关论文
共 66 条
[1]  
Ayyar BV(2016)Coming-of-Age of Antibodies in Cancer Therapeutics Trends Pharmacol Sci 37 1009-1028
[2]  
Arora S(2010)Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy Cancer Treat Rev 36 458-467
[3]  
O’Kennedy R(2016)Novel immunotherapies in lymphoid malignancies Nat Rev Clin Oncol 13 25-40
[4]  
Seimetz D(2018)Redirecting T cells to hematological malignancies with bispecific antibodies Blood 131 30-38
[5]  
Lindhofer H(2009)Bispecific T-cell engaging antibodies for cancer therapy Cancer Res 69 4941-4944
[6]  
Bokemeyer C(2017)Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL) Ann Oncol 28 2009-2012
[7]  
Batlevi CL(2018)T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics Pharmacol Ther 182 161-175
[8]  
Matsuki E(2007)Two heads are better than one Nat Biotechnol 25 1233-1234
[9]  
Brentjens RJ(2018)Next generation antibody drugs: pursuit of the “high-hanging fruit” Nat Rev Drug Discov 17 197-223
[10]  
Velasquez MP(2005)BiTEs: bispecific antibody constructs with unique anti-tumor activity Drug Discov Today 10 1237-1244